- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04290455
Treatment of Anterior Blepharitis With Microblepharoexfoliation Procedure
The Efficacy of Microblephararoexfoliation in the Treatment of Anterior Blepharitis
Study Overview
Status
Conditions
Detailed Description
This study will be prospective, randomized, paired eye trial. Twenty patients with symptomatic anterior blepharitis with or without meibomian gland dysfunction who have a lash contamination score >1 and the Standard Patient Evaluation of Eye Dryness Questionnaire score (SPEED score) >= 1 will be included in the study. The criteria for grading of lashes contamination is defined as: 0= Clear lashes, 1=Slight contamination (involvement of lashes >0 but <25%), 2=Mild (>=25% but < 50%), 3=Moderate (>=50% but < 75%), and 4=Severe (>=75%). Patients will be recruited from the Dry Eye Clinic, Jules Stein Eye Institute, UCLA. The informed consent will be obtained from each patient. Patients who have been given a topical corticosteroid within 6 weeks before entering the study or need a topical corticosteroid or topical antibiotics as an adjunct to lid cleansing will be excluded from the study. Patients with concurrent conjunctivitis or keratopathy will also be excluded. Previous topical medications before patients enter the study such as anti-glaucoma medications and artificial tears will be continued.
One of the patients' eyes will be simply randomized into the interventional group in which the BlephExTM device(1) will be used to perform eyelid margin and lash cleansing. The other eye will be entered into the control group in which eyelid cleansing in a conventional way will be done using Optase wipes. In the screening visit, the Standardized Patient Evaluation of Eye Dryness (SPEED) questionnaire score and eyelid contamination will be assessed to recruit eligible patients. Before eyelid cleansing, images of the eyelid margin will be obtained by Oculus Keratograph 5M, Wetzlar, Germany and will be used to grade lashes contamination and lid margin redness by two independent observers. Parameters of interest of each eye will be evaluated separately. The primary outcomes are symptoms which will be scored using the Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED)(2) and lashes contamination which will be graded as described above. Other outcomes of interest are lid margin redness, and the number of preservative free artificial tears used per day. The lid margin redness is graded as 0=Clear/white 1=Slight redness 2=Mild redness 3=Moderate redness 4=Severe redness. Patients will also be evaluated for concurrent meibomian gland dysfunction by evaluating meibum quality and expressibility of meibomian glands according to the International Workshop on Meibomian Gland dysfunction 2011(3). Meibum quality is assessed in each of eight glands of the central third of the lower lid on a scale of 0 to 3 for each gland: 0, clear; 1, cloudy; 2, cloudy with debris (granular); and 3, thick, like toothpaste (total score range, 0-24). Expressibility is assessed on a scale of 0 to 3 in five glands in the lower or upper lid, according to the number of glands expressible: 0, all glands; 1, three to four glands; 2, one to two glands; and 3, no glands. Patients who have minimally altered secretion grade ≥ 2-4 and expressibility ≥ 1 will be diagnosed with MGD. The images of eyelids will be taken again immediately after eyelid cleansing and eyelid contamination scores will be evaluated. The patient will then be instructed to perform lid cleansing at home once a day with eyelid cleansing wipes (Optase) for 21 days. The technique will be demonstrated to the patient in clinic. The follow-up visits will be at 21 days. At the follow-up visit, all of the data obtained in the screening visit will be repeated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Stein Eye Institute, UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- anterior blepharitis with or without meibomian gland dysfunction who have a lash contamination score >1 and the Standard Patient Evaluation of Eye Dryness Questionnaire score (SPEED score) >= 1
Exclusion Criteria:
- Patients who have been given a topical corticosteroid within 6 weeks before entering the study or need a topical corticosteroid or topical antibiotics as an adjunct to lid cleansing will be excluded from the study.
- Patients with concurrent conjunctivitis or keratopathy will also be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment arm
using the microblepharoexfoliative procedure
|
The device will be used to clean both upper and lower eyelid in the office visit.
Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
|
Active Comparator: control arm
using eyelid wipe (Optase)
|
Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from the baseline of the Standardized Patient Evaluation of Eye Dryness (SPEED) questionnaire score 21 days after treatment
Time Frame: Day 21 after treatment
|
Day 21 after treatment
|
|
Change from the baseline grading of lashes contamination 21 days after treatment
Time Frame: Day 21 after treatment
|
The criteria for grading of lashes contamination is defined as severity of debris on lashes: 0= Clear lashes, 1=Slight contamination (involvement of lashes >0 but <25%), 2=Mild (>=25% but < 50%), 3=Moderate (>=50% but < 75%), and 4=Severe (>=75%).
|
Day 21 after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lid margin redness
Time Frame: Baseline and Day 21 after treatment
|
The lid margin redness is graded as 0=Clear/white 1=Slight redness 2=Mild redness 3=Moderate redness 4=Severe redness.
|
Baseline and Day 21 after treatment
|
Frequency of preservative-free artificial tear eye drops used per day
Time Frame: Baseline and Day 21 after treatment
|
Baseline and Day 21 after treatment
|
|
Degree of meibomian gland dysfunction
Time Frame: Baseline and Day 21 after treatment
|
Assessment of meibum quality and expressibility of meibomian gland according to the International Workshop on Meibomian Gland dysfunction 2011(3).
Meibum quality is assessed in each of eight glands of the central third of the lower lid on a scale of 0 to 3 for each gland: 0, clear; 1, cloudy; 2, cloudy with debris (granular); and 3, thick, like toothpaste (total score range, 0-24).
Expressibility is assessed on a scale of 0 to 3 in five glands in the lower or upper lid, according to the number of glands expressible: 0, all glands; 1, three to four glands; 2, one to two glands; and 3, no glands.
Patients who have minimally altered secretion grade ≥ 2-4 and expressibility ≥ 1 will be diagnosed with MGD.
|
Baseline and Day 21 after treatment
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Ngo W, Situ P, Keir N, Korb D, Blackie C, Simpson T. Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. Cornea. 2013 Sep;32(9):1204-10. doi: 10.1097/ICO.0b013e318294b0c0.
- Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1922-9. doi: 10.1167/iovs.10-6997a. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-000084
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anterior Blepharitis
-
Shaare Zedek Medical CenterRecruiting
-
Laboratoires TheaCompleted
-
NTC srlCompletedBilateral Blepharitis (Disorder)Italy
-
Tarsus Pharmaceuticals, Inc.RecruitingDemodex BlepharitisUnited States
-
Istanbul University - Cerrahpasa (IUC)Koç UniversityCompleted
-
Istanbul University - Cerrahpasa (IUC)Koç UniversityCompleted
-
Sun Pharmaceutical Industries LimitedCompletedActive, Symptomatic BlepharitisUnited States
-
Universidad Nacional de ColombiaCompletedChronic BlepharitisColombia
-
Tissue Tech Inc.National Eye Institute (NEI)Completed
-
Tehran University of Medical SciencesCompletedPosterior BlepharitisIran, Islamic Republic of
Clinical Trials on Microblepharoexfoliative procedure with BlephEx™
-
Treace Medical Concepts, Inc.RecruitingHallux Valgus | Metatarsus AdductusUnited States
-
Biosense Webster, Inc.Completed
-
Medtronic Spinal and BiologicsCompletedLumbar Spine Degeneration | Degenerative Lumbar Spine Causing Back and/or Leg PainSpain, Germany, Belgium, Israel, Portugal, Austria, Canada, Czechia, Greece, Italy, Netherlands, Poland, Slovakia, United Kingdom
-
Lombard MedicalCompletedAbdominal Aortic AneurysmCzech Republic, Germany, Poland, Spain, United Kingdom
-
Cartiheal (2009) LtdCompletedCartilage or Osteochondral Defects in the KneeAustria, Belgium, Slovenia, Italy, Israel, Poland, Romania, Serbia
-
Smart Medical Systems Ltd.CompletedColorectal Cancer | Adenoma | PolypIsrael
-
M.D. Anderson Cancer CenterTriSalus Life SciencesRecruiting
-
Smart Medical Systems Ltd.CompletedColorectal Cancer | Adenoma | PolypIsrael, Germany
-
University Hospital, Clermont-FerrandCompletedPneumothorax | Hemothorax | Pleural EffusionFrance
-
ASTORA Women's HealthCompletedPelvic Organ ProlapseUnited States, Belgium, France, Germany, Netherlands, Spain, United Kingdom